Viromed Medical AG, a medical technology company specializing in cold plasma technology, has entered into an exclusive global distribution partnership with NEBU-TEC International med. Produkte Eike Kern GmbH to commercialize its PulmoPlas® platform for veterinary applications. The collaboration will integrate Viromed's cold plasma technology with NEBU-TEC's inhalation and nebulization devices, focusing initially on pulmonary diseases in horses.
The partnership grants NEBU-TEC worldwide exclusive distribution rights for veterinary use of PulmoPlas®, which combines cold plasma with aerosol delivery. According to the announcement, the market launch for PulmoPlas® vet is expected later in 2026, with no regulatory approval required for veterinary applications. The companies believe this addresses a significant market need, particularly in the European equine market and equestrian sports, where respiratory conditions are common among horses.
Viromed's CEO Uwe Perbandt stated that the partnership represents an important step in international commercialization, opening up new fields in veterinary medicine and potentially human medicine later. NEBU-TEC's Managing Director Eike Kern highlighted that combining inhalation with cold plasma creates innovative therapeutic possibilities for both animals and humans.
The devices used by NEBU-TEC are Class IIa medical devices under the EU Medical Device Regulation (MDR), which would allow future human use of PulmoPlas® med with the same nebulization technology. Viromed, which has been publicly traded since October 2022, is expanding its strategic partnerships in cold plasma technology through this agreement.
For more information, visit Viromed Medical AG or NEBU-TEC. The original press release is available on NewMediaWire.
